Personalized, Precision Medicine to Cure Alzheimer’s Dementia: Approach #1
The goal of the treatment for Alzheimer’s dementia (AD) is the cure of dementia. A literature review revealed 18 major elements causing AD and 29 separate medications that address them. For any individual with AD, one is unlikely to discern which major causal elements produced dementia. Thus, for pe...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-03-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/25/7/3909 |
| _version_ | 1797212506317389824 |
|---|---|
| author | Jeffrey Fessel |
| author_facet | Jeffrey Fessel |
| author_sort | Jeffrey Fessel |
| collection | DOAJ |
| description | The goal of the treatment for Alzheimer’s dementia (AD) is the cure of dementia. A literature review revealed 18 major elements causing AD and 29 separate medications that address them. For any individual with AD, one is unlikely to discern which major causal elements produced dementia. Thus, for personalized, precision medicine, all causal elements must be treated so that each individual patient will have her or his causal elements addressed. Twenty-nine drugs cannot concomitantly be administered, so triple combinations of drugs taken from that list are suggested, and each triple combination can be administered sequentially, in any order. Ten combinations given over 13 weeks require 2.5 years, or if given over 26 weeks, they require 5.0 years. Such sequential treatment addresses all 18 elements and should cure dementia. In addition, any comorbid risk factors for AD whose first presence or worsening was within ±1 year of when AD first appeared should receive appropriate, standard treatment together with the sequential combinations. The article outlines a randomized clinical trial that is necessary to assess the safety and efficacy of the proposed treatments; it includes a triple-drug Rx for equipoise. Clinical trials should have durations of both 2.5 and 5.0 years unless the data safety monitoring board (DSMB) determines earlier success or futility since it is uncertain whether three or six months of treatment will be curative in humans, although studies in animals suggest that the briefer duration of treatment might be effective and restore defective neural tracts. |
| first_indexed | 2024-04-24T10:43:28Z |
| format | Article |
| id | doaj.art-80cecc45af6a462a93047385d603f027 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-04-24T10:43:28Z |
| publishDate | 2024-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-80cecc45af6a462a93047385d603f0272024-04-12T13:20:06ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672024-03-01257390910.3390/ijms25073909Personalized, Precision Medicine to Cure Alzheimer’s Dementia: Approach #1Jeffrey Fessel0Clinical Medicine, Department of Medicine, University of California, 2069 Filbert Street, San Francisco, CA 94123, USAThe goal of the treatment for Alzheimer’s dementia (AD) is the cure of dementia. A literature review revealed 18 major elements causing AD and 29 separate medications that address them. For any individual with AD, one is unlikely to discern which major causal elements produced dementia. Thus, for personalized, precision medicine, all causal elements must be treated so that each individual patient will have her or his causal elements addressed. Twenty-nine drugs cannot concomitantly be administered, so triple combinations of drugs taken from that list are suggested, and each triple combination can be administered sequentially, in any order. Ten combinations given over 13 weeks require 2.5 years, or if given over 26 weeks, they require 5.0 years. Such sequential treatment addresses all 18 elements and should cure dementia. In addition, any comorbid risk factors for AD whose first presence or worsening was within ±1 year of when AD first appeared should receive appropriate, standard treatment together with the sequential combinations. The article outlines a randomized clinical trial that is necessary to assess the safety and efficacy of the proposed treatments; it includes a triple-drug Rx for equipoise. Clinical trials should have durations of both 2.5 and 5.0 years unless the data safety monitoring board (DSMB) determines earlier success or futility since it is uncertain whether three or six months of treatment will be curative in humans, although studies in animals suggest that the briefer duration of treatment might be effective and restore defective neural tracts.https://www.mdpi.com/1422-0067/25/7/3909Alzheimer’s dementiacure of dementia18 elements of pathogenesisdrugs addressing each elementsequential administration of triple-drug treatments |
| spellingShingle | Jeffrey Fessel Personalized, Precision Medicine to Cure Alzheimer’s Dementia: Approach #1 International Journal of Molecular Sciences Alzheimer’s dementia cure of dementia 18 elements of pathogenesis drugs addressing each element sequential administration of triple-drug treatments |
| title | Personalized, Precision Medicine to Cure Alzheimer’s Dementia: Approach #1 |
| title_full | Personalized, Precision Medicine to Cure Alzheimer’s Dementia: Approach #1 |
| title_fullStr | Personalized, Precision Medicine to Cure Alzheimer’s Dementia: Approach #1 |
| title_full_unstemmed | Personalized, Precision Medicine to Cure Alzheimer’s Dementia: Approach #1 |
| title_short | Personalized, Precision Medicine to Cure Alzheimer’s Dementia: Approach #1 |
| title_sort | personalized precision medicine to cure alzheimer s dementia approach 1 |
| topic | Alzheimer’s dementia cure of dementia 18 elements of pathogenesis drugs addressing each element sequential administration of triple-drug treatments |
| url | https://www.mdpi.com/1422-0067/25/7/3909 |
| work_keys_str_mv | AT jeffreyfessel personalizedprecisionmedicinetocurealzheimersdementiaapproach1 |